Different effects of dopamine and dopexamine on the isolated perfused rat kidney

British Journal of Anaesthesia

Volumn 83, Issue 6, 1999, Pages 898-902

  Kirchhoff, K ^a   Leuwer, M ^a   Thum, P ^a   Bornscheuer, A ^a   Piepenbrock, S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Kidney, function; Model, kidney; Pharmacology, dopamine; Pharmacology, dopexamine; Rat

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; DOPEXAMINE; SODIUM;

ANIMAL TISSUE; ARTICLE; GLOMERULUS FILTRATION RATE; ISOLATED KIDNEY; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM ABSORPTION; SODIUM EXCRETION; URINE VOLUME;

EID: 0032703749     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/83.6.898     Document Type: Article

References (29)

1. Foulds RA. Clinical developement of dopexamine hydrochloride (Dopacard) and an overview of its hemodynamic effects. Am J Cardiol 1988; 62: 41-5C
2. Smith GW, O'Connor SE. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). Am J Cardiol 1988; 62: 9-17C
3. Lokhandwala MF, Jandhyala BS. Effects of dopaminergic agonists on organ blood flow and function. Clin Int Care 1992; 3: 12-16
4. Maynard ND, Bihari DJ, Dalton RN, Smithies MN, Mason RC. Increasing splanchnic blood flow in the critically ill. Chest 1995; 108: 1648-54
5. Martin SW, Broadley KJ. Renal vasodilation by dopexamine and fenoldopam due to α1-adrenoceptor blockade. Br J Pharmacol 1994; 112: 595-603
6. Nedergaard OA. Effect of dopexamine hydrochloride on sympathetic neuroeffector transmission in rabbit isolated pulmonary artery. Pharmacol Toxicol 1996; 78: 161-6
7. Nedergaard OA. Effect of dopexamine hydrochloride on contractions of rabbit isolated aorta evoked by various agonists. Pharmacol Toxicol 1994; 74: 43-9
8. Poison RJ, Park GR, Lindop MJ, Farman JV, Calne RY, Williams R. The prevention of renal impairement in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987; 42: 15-19
9. Schurek HJ, Brecht JP, Lohfert H, Hierholzer K. The basic requirements for the function of the isolated cell free perfused rat kidney. Pflügers Arch 1975; 354: 349-65
10. Kirchhoff K, Bub A, Marxen P, Forssmann WG. Urodilatin inhibits sodium reabsorption in the isolated perfused rat kidney. Exp Nephrol 1994; 2: 351-7
11. Schmidt FH. Die enzymatische Bestimmung von Glukose und Fruktose nebeneinander. Klin Wochenschrift 1961; 39: 1244
12. Martin SW, Broadley KJ. Atypical antagonism of D1-receptor-mediated vasodilator responses in the perfused kidney by SCH23390. Pharmacol Res 1995; 31: 289-97
13. Jose PA, Felder RA, Monsma FJ, Sibley DR, Mouradian MM. Molecular biology of dopamine receptors: an overview. In: Soares-da-Silva P, ed. Cardiovascular and Renal Actions of Dopamine. Advances in the biosciences, vol. 88. Oxford: Pergamon Press, 1993; 51-61
14. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 1991; 5: 3023-30
15. Missale C, Pizzi M, Memo M, Picotti GB, Carruba MO, Spano PF. Postsynaptic D1 and D2 dopamine receptors are present in rabbit renal and mesenteric arteries. Neurosci Lett 1985; 61: 207-11
16. Bell C. Involvement of endogenous dopamine in control of renal function. In: Soares-da-Silva P, ed. Cardiovascular and Renal Actions of Dopamine. Advances in the Biosciences. vol. 88. Oxford: Pergamon Press, 1993; 1-20
17. Goldberg LI, Rajfer SI. Dopamine receptors: Applications in clinical cardiology. Circulation 1985; 72: 245-8
18. Goldberg LI. The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 14: S19-27
19. Stoner JD, Bolen JL Harrison DC. Comparison of dobutamine and dopamine in treatment of severe heart failure. Br Heart J 1988; 39: 536-9
20. Brown RA, Dixon J, Farmer JB, et al. Dopexamine: A novel agonist at peripheral dopamine receptors and β2-adrenoceptors. Br J Pharmacol 1985; 85: 599-608
21. Smith GW, Hall JC, Farmer JB, Simpson WT. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and β2-adrenoceptors in dog. J Pharmacol 1987; 39: 636-41
22. Brown RA, Farmer JB, Hall JC, et al. The effects of dopexamine on the cardiovascular system of the dog. Br J Pharmacol 1985; 85: 609-19
23. Lang RM, Borow KM, Neumann A, et al. Role of the beta2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride. Am J Cardiol 1988; 62: 46-52C
24. Jackson NC, Taylor SH, Frais MA. Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction. Am J Cardiol 1988; 62: 73-7C
25. Mitchell PD, Smith GW, Wells E, West PA. Inhibition of uptake-I by dopexamine hydrochloride (in vitro). Br J Pharmacol 1987; 9: 265-70
26. Magriri F, Foulds R, Roberts N, Macchi G, Mondadori C, Zanchetti A. Human renovascular effects of dopexamine hydrochloride: a novel agonist at peripheral dopamine and β2 adrenoceptors. Eur J Clin Pharmacol 1987; 32: 1-4
27. Mousdale S, Clyburn PA, Mackie AM, Groves ND, Rosen M. Comparison of the effects of dopamine, dobutamine and dopexamine upon renal blood flow: a study in normal healthy volunteers. Br J Clin Pharmacol 1988; 25: 555-60
28. Tan LB, Smith SA, Murray RG, Littler WA. Renal response to dopexamine in low output heart failure. Clin Sci 1986; 71: 56P
29. Leier CV, Binkley PF, Carpenter J, Randolph PH, Unverferth DV. Cardiovascular pharmacology of dopexamine in low output congestive heart failure. Am J Cardiol 1988; 62: 94-9